KEAP1 and multiple sclerosis: Upon dissociated from Keap1, Nrf2 is translocated into the nucleus and then initiates cytoprotective gene transcription to counteract oxidative stress and modulate redox status balance.23 In keeping with this, the Nrf2‐activating drug dimethyl fumarate has been approved by the FDA for the treatment of multiple sclerosis,70 in part based on its anti‐oxidative effects.